RHAPSODY - Risk Assessment and ProgreSsiOn of DIabetes

​RHAPSODY is focused on assessing the risk of progression of pre-diabetes to overt diabetes and of rapid deterioration of type 2 diabetes (T2D). This is achieved by a multi-omics analysis of large European cohorts. The Systems Medicine group will be provided metabolomics data for over 6000 patients progressing into type 2 diabetes.

RHAPSODY is a unique collaboration of leading public and private research groups, which will include over 100 researchers operating in 7 different scientific work packages. RHAPSODY is based on the availability of large population prospective cohorts, with unique collection of genetic, biochemical and clinical data. RHAPSODY will also beneficiate of extensive and unique resources developed in previous IMI projects. Combining new and existing data with the expertise of its partners, RHAPSODY will develop novel biomarkers to refine diagnosis leading to better patient stratification, promote prevention, and support innovative drug discovery for personalized management of diabetes.


The stated goal of RHAPSODY is to define a molecular taxonomy of type 2 diabetes mellitus (T2D) that will support patient segmentation, inform clinical trial design, and the establishment of regulatory paths for the adoption of novel strategies for diabetes prevention and treatment.


The consortium groups 20 academic research laboratories focused especially on diabetes research (including 3 university hospitals with extensive experience following long-term diabetes cohorts and biobank), two SMEs (one specialised in lipid analyses and the other in scientific project management) and four well-established pharmaceutical and biotechnology establishments, all part of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Responsible editor